The Vaccines Related Biological Products Advisory Committee to the Food and Drug Administration voted unanimously to recommend a monovalent JN.1 lineage as the 2024 vaccine against SARS-CoV-2.  This decision was based on epidemiologic studies indicating the predominance of JN.1.  Manufacturers of vaccine for 2024-2025 will follow the FDA requirement with the updated product available during the fall.  The adoption of mRNA technology for COVID vaccines allows for rapid selection of the predominant circulating strain to optimize antigenicity and hence protection.